First order after being selected as priority supplier… Company says “additional orders for consumables and services expected”
Bio analytical equipment company Aligned Genetics has received an order worth about USD 400,000 (approximately KRW 500 million) from global pharmaceutical company Novartis for its automated cell analysis system “LUNA-FX7.” According to the company, this is the first order since it was selected as a global Preferred Supplier by Novartis in August, and the amount is equivalent to about 4% of its previous year’s revenue.
The company stated that in March this year it underwent the first round of evaluation for Novartis’ global automated cell analysis system procurement project, during which its technological capabilities, service support capacity, and supply pricing were assessed, and that it was selected as a supplier in August after achieving the highest final aggregate score.
The initial batch will be supplied to three Novartis sites in Switzerland and in Boston and San Diego in the United States. The order amount covers the supply of equipment only and does not include dedicated consumables and services such as measurement slides and reagents. The company expects additional orders related to consumables and services.
Because automated cell analysis systems are structured so that dedicated consumables continue to be used even after installation, an increase in installation sites can lead to higher consumables and service revenue. The company plans to expand supply to other Novartis research, development, and production facilities.
LUNA-FX7 is a device capable of simultaneously analyzing up to eight samples and is used in biopharmaceutical research and development, as well as in the production and quality control (QC) of cell therapies. Aligned Genetics has previously supplied its products to U.S.-based Vertex Pharmaceuticals. It operates wholly owned local subsidiaries in the United States, Europe, and Japan to provide product supply, technical support, and maintenance.
A company representative said, “It is significant that the supply agreement concluded after a competitive evaluation has led to an actual order,” adding, “Novartis issues separate purchase orders for each installation site, so the amounts are divided and were not disclosed in a separate regulatory filing.” The representative continued, “Based on our selection as a Preferred Supplier for Novartis, we will seek to expand additional supply opportunities and thereby increase overseas revenue.”
Choi Yong-seok
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
